MBMarianne F. L. van Den Broek

Marianne F. L. van Den Broek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marianne F. L. van Den Broek has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Potential transfer of orally administered probiotics to the upper respiratory tract in children with otitis media with effusion

    by J. Van Malderen, I. De Boeck, M.F.L. van Den Broek, M. Hiel, J. Jörissen, I. Tuyaerts, S. Bakelants, I. Spacova, O.M. Vanderveken, A.N. Boudewyns, et al.

    The upper respiratory tract (URT) microbiome is increasingly recognised as a key determinant of airway health, yet the potential of probiotics to beneficially modulate these communities remains largely unexplored, despite the high burden of URT infections such as otitis media (OM). This randomised controlled trial investigated the migration of two model probiotic strains, Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, to different URT niches in 37 children with otitis media with effusion (OME) treated daily with oral oil drops for one month. URT samples from the adenoids, and nasopharynx were analysed with species-specific qRT-PCR and 16S amplicon sequencing. L. rhamnosus GG-like bacteria were detected in 4/19 of treated patients compared to 0/18 in the control group. Probiotic treatment with oral oil droplets modestly increased the prevalence of L. rhamnosus GG-like bacteria in the nasopharynx and adenoids (from 0% to 16.67% and 15.79% respectively), and a slight positive association was observed with the abundance of Dolosigranulum pigrum (effect size = 0.13). Interestingly, other factors, such as maternal antibiotic use after birth, were associated with a notable higher abundance of Moraxella catarrhalis/nonliquefaciens (Maaslin effect size = 5.10), and a lower abundance of Streptococcus pneumoniae/pseudopneumoniae (Maaslin effect size = −2.27). In conclusion, this study suggests that oral probiotics might modulate the URT microbiome in ways relevant to OM, although the magnitude and direction of effects likely depend on the specific strains used. The trial was registered at ClinicalTrials.gov under B300201731908.

  • Open Access

    Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections

    by Irina Spacova, Ilke De Boeck, Eline Cauwenberghs, Lize Delanghe, Peter A. Bron, Tim Henkens, Alix Simons, Imane Gamgami, Leentje Persoons, Ingmar Claes, et al.

    Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut‐targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the formulation of a throat spray with live lactobacilli exhibiting several in vitro mechanisms of action against respiratory viral infections, including induction of interferon regulatory pathways and direct inhibition of respiratory viruses. Rational selection of Lactobacillaceae strains was based on previously documented beneficial properties, up‐scaling and industrial production characteristics, clinical safety parameters, and potential antiviral and immunostimulatory efficacy in the URT demonstrated in this study. Using a three‐step selection strategy, three strains were selected and further tested in vitro antiviral assays and in formulations: Lacticaseibacillus casei AMBR2 as a promising endogenous candidate URT probiotic with previously reported barrier‐enhancing and anti‐pathogenic properties and the two well‐studied model strains Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 that display immunomodulatory capacities. The three strains and their combination significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV‐229E coronavirus in co‐culture models with bacteria, virus, and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway‐inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form. Thus, the developed spray with live lactobacilli will be further explored in the clinic as a potential broad‐acting live biotherapeutic strategy against respiratory viral diseases.


  • Open Access

    Live biotherapeutic throat spray for respiratory virus inhibition and interferon pathway induction

    by Irina Spacova, Ilke De Boeck, Eline Cauwenberghs, Lize Delanghe, Peter A. Bron, Tim Henkens, Alix Simons, Imane Gamgami, Leentje Persoons, Ingmar Claes, et al.

    Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut-targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the selection and formulation of a broad-acting throat spray with live lactobacilli which induce interferon regulatory pathways and are able to inhibit respiratory viruses. Rational selection of Lactobacillaceae strains was based on safety, applicability, and potential antiviral and immunostimulatory efficacy in the URT. Three strains, Lacticaseibacillus casei AMBR2, Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV-229E coronavirus in co-culture models with bacteria, virus and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway-inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form.